Genentech’s Perjeta Passes Neoadjuvant Pathway Test, FDA Panel Says
Executive Summary
Oncologic Drugs Advisory Committee members backing a claim for neoadjuvant treatment of early breast cancer cite pertuzumab’s special circumstances in cautioning that they are not opening the door wide to accelerated approval of other agents under an FDA draft guidance.